Table 2.

Comparison of the total BDI-II scores in various subgroups in the total study population (N=60). P values refer to results of Mann-Whitney U tests, unless otherwise indicated.

	Total BDI-II score
	Number of subjects	Mean ± SD	p value
Gender
male	37	10 ± 8	0.83
female	23	10 ± 9
Tumor group
newly-diagnosed	34	9 ± 9	0.31
recurrent	26	10 ± 7
Tumor typea
glioma	49	9 ± 8	0.88
meningioma	10	11 ± 10
DNET	1	(10)
Tumor gradeb,c
Grade I	7	10 ± 9	0.58
Grade II	9	12 ± 8
Grade III	10	7 ± 4
Grade IV	31	10 ± 8
Tumor lateralizationc
left	23	11 ± 9	0.64
right	34	9 ± 8
bilateral/midline	3	9 ± 8
Tumor localizationc
frontal	29	11 ± 8	0.26
temporal	13	8 ± 10
parietal	9	9 ± 8
occipital	5	5 ± 4
otherd	4	11 ± 12
Antiepileptic treatment
yes	30	10 ± 9	0.82
no	30	9 ± 8
SSRI treatment
yes	10	15 ± 10	0.017
no	50	8 ± 7
Steroid usee
yes	19	11 ± 8	0.43
no	40	9 ± 8

^a: DNET has not included;

^b: three patients with no surgery have not been included;

^c: Kruskal-Wallis test;

^d: located outside the cerebral lobes (all meningiomas);

^e: one patient had no data available on steroid use. SD: standard deviation.